Dilip Shanghvi, the founder of Sun Pharmaceutical Industries, is poised to make a significant move in the pharmaceutical world with a $12.5 billion acquisition of Organon & Co., a US-based company. This acquisition marks Sun Pharma's largest overseas deal and is notable as the biggest purchase by an Indian company since Tata Steel acquired Corus in 2007. Sun Pharma's growth has been largely driven by acquisitions, with Shanghvi focusing on distressed companies that offer strategic advantages. Notable past acquisitions include Ranbaxy Laboratories, which expanded Sun Pharma's international footprint despite its regulatory challenges, and Taro Pharmaceuticals, where a patient acquisition strategy allowed for gradual control over a profitable dermatology segment. Sun Pharma's approach emphasizes profitability over mere revenue growth, maintaining a focus on niche therapeutic areas like dermatology and oncology. Shanghvi's personal style mirrors his business strategy, characterized by analytical decision-making and a preference for controlled, long-term growth.